Followers | 43 |
Posts | 5751 |
Boards Moderated | 0 |
Alias Born | 04/12/2021 |
Thursday, November 25, 2021 12:20:41 PM
“This prospectus supplement supplements the prospectus dated August 6, 2021 (as supplemented to date, the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-258100) filed with the Securities and Exchange Commission (the “SEC”) on July 22, 2021 and declared effective by the SEC on August 6, 2021.
The Prospectus and this prospectus supplement relate to (i) the resale of 4,286,500 shares of common stock, par value $0.0001 per share (the “Common Stock”) issued in connection with the Domestication (as defined in the Prospectus) by certain of the selling securityholders named in the Prospectus (each a “selling securityholder” and, collectively, the “selling securityholders”), (ii) the resale of 69,655,827 shares of Common Stock issued in connection with the Business Combination (as defined in the Prospectus) by certain of the selling securityholders, (iii) the resale of 20,000,000 shares of common stock issued in the PIPE Financing (as defined in the Prospectus) by certain of the selling securityholders, and (iv) the issuance by us and resale of 1,702,729 shares of Common Stock reserved for issuance upon the exercise of certain outstanding options to purchase Common Stock.
Common Stock Warrants
In connection with a term loan that the Company entered into during fiscal year 2017, 63,491 common stock warrants were issued to the lender, and recorded at fair value within additional paid-in capital in stockholders’ equity (deficit). Fair value was determined using the Black-Scholes Option Pricing Model. There were no common stock warrants issued during the three and nine months ended September 30, 2021 and 2020. During the three months ended June 30, 2021, all common stock warrants were net exercised and the Company issued 62,722 Common Stock shares to the lender.
Common stock warrants as of December 31, 2020 were as follows:
December 31, 2020 Outstanding Warrants Number of Warrants Exercise Price Expiration Date Common stock 63,491 $ 0.12 9/7/2027 Total outstanding common stock warrants 63,491
Common Stock Reserved for Future Issuance
Shares of common stock reserved for future issuance on an as-if converted basis, were as follows:
September 30,
2021 December 31,
2020 Stock options issued and outstanding 8,316,886 5,145,547 Shares available for grant under 2021 Equity Incentive Plan 14,850,960 —
Shares available for grant under 2021 Employee Stock Purchase Plan
1,244,900 — Convertible preferred stock — 52,175,965 Common stock warrants outstanding — 63,491 Shares available for grant under 2017 Equity Incentive Plan — 2,349,673 Total shares of common stock reserved
”
https://www.otcmarkets.com/filing/html?id=15321425&guid=CBywkWCEDcwfJth
my posts are always theory and not financial advice
Recent NAUT News
- Nautilus Biotechnology Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024 • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/07/2024 05:15:12 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/06/2024 09:39:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:49:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:46:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:42:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:34:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:30:01 PM
- Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:26:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/28/2024 12:25:19 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/28/2024 12:15:43 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:04:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:03:30 PM
- Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 09:17:26 PM
- Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award • GlobeNewswire Inc. • 11/30/2023 01:00:00 PM
- Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development • GlobeNewswire Inc. • 11/01/2023 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/31/2023 08:02:46 PM
- Nautilus Biotechnology Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 10/31/2023 12:05:00 PM
- Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023 • GlobeNewswire Inc. • 10/11/2023 12:05:00 PM
- Nautilus Biotechnology to Participate in Upcoming September Investor Conferences • GlobeNewswire Inc. • 09/06/2023 11:30:00 AM
- Nautilus Biotechnology to Participate in Upcoming August Investor Conferences • GlobeNewswire Inc. • 08/04/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM